Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Johnson & Johnson

Johnson & Johnson has announced an upcoming investor conference call to discuss its fourth-quarter results, scheduled for a future date. This event...

Johnson & Johnson announced an investor call for Q4 results. The stock declined following the news about financial insights.

The U.S. Food and Drug Administration said on Monday it has granted a national priority voucher to Johnson & Johnson's treatment for a type of bloo...

US FDA grants priority voucher to J&J's blood cancer treatment

Johnson & Johnson shares are currently experiencing a notable increase, attributed largely to the strong performance of the Pharmaceuticals sector....

Johnson & Johnson's stock surges on strong Pharma performance. FDA approvals for Tecvayli and Akeega boost growth outlook amid positive sector sent...

Johnson & Johnson is experiencing an upward price movement, largely influenced by the Pharmaceuticals sub-sector, which is also seeing significant...

Johnson & Johnson's stock rises on FDA approval of Akeega for prostate cancer, boosting treatment options. Citigroup and Morgan Stanley raise price...

RBC Capital has maintained an Outperform rating on Johnson & Johnson and raised its price target to $230. The stock price has reached an all-time h...

RBC Capital raises Johnson & Johnson's price target to $230, maintaining an Outperform rating. Strong quarterly results and positive analyst sentim...

Johnson & Johnson announced promising results from the Phase 3 MajesTEC-3 study, demonstrating that the combination of TECVAYLI and DARZALEX FASPRO...

Johnson & Johnson's Phase 3 study shows TECVAYLI and DARZALEX FASPRO cut disease progression risk by 83% in multiple myeloma. Social media buzz com...

Johnson & Johnson is currently facing a temporary order from a Texas judge mandating the company and its former subsidiary, Kenvue, to register wit...

Texas judge orders J&J to register or face business ban. Positive CARTITUDE-4 results show 80% remission at 2.5 years.

Johnson & Johnson's stock has experienced a decline of 1.39%, coinciding with a broader downturn in the health care sector, which fell by 0.73%. Wi...

Johnson & Johnson's stock declines amid health care sector downturn. Negative sentiment on social media highlights challenges for pharmaceutical st...

Johnson & Johnson has announced a partnership with actress Naomi Watts to promote eye health for women over 40. This initiative highlights the impo...

Johnson & Johnson partners with Naomi Watts to promote eye health for women over 40. The initiative stresses routine exams amid low engagement in v...

Johnson & Johnson is currently experiencing upward movement, primarily influenced by the Pharmaceuticals sub-sector, which is also rising significa...

JNJ rises on strong Pharmaceuticals sector performance. Barclays raises price target to 197 amid bearish net flow concerns.

Johnson & Johnson's stock has recently declined, reaching lows after a notable drop attributed to the Pharmaceuticals sub-sector, which is also exp...

Johnson & Johnson's stock declines amid a downturn in the Pharmaceuticals sub-sector. This follows a recent milestone of surpassing a $500 billion...

Johnson & Johnson is on track for a record high close, bolstered by optimism regarding upcoming therapeutic options for Sjögren's syndrome. Recentl...

Johnson & Johnson gains traction from positive multiple myeloma survival rates and upcoming ASH 2025 conference focus on its therapies. Tecvayli's...

The pharmaceutical powerhouse Johnson & Johnson (NYSE: JNJ) has significantly outperformed its competitor Pfizer (NYSE: PFE) this year. JNJ's stock...

JNJ Stock vs. PFE Stock: Which Pharmaceutical Giant Is A Better Buy?

Johnson & Johnson is experiencing a notable price increase, aligning with the broader market's upward movement. Recent reports indicate that the co...